ABVX
AbivaxABVX
ABVX
About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Employees: 69
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
18% more capital invested
Capital invested by funds: $199M [Q1] → $235M (+$36.1M) [Q2]
1.76% less ownership
Funds ownership: 50.08% [Q1] → 48.33% (-1.76%) [Q2]
7% less funds holding
Funds holding: 46 [Q1] → 43 (-3) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
11%
downside
Avg. target
$96
21%
upside
High target
$112
42%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Allison Bratzel | 42%upside $112 | Overweight Maintained | 29 Jul 2025 |
Piper Sandler Christopher Raymond | 11%downside $70 | Overweight Maintained | 23 Jul 2025 |
LifeSci Capital Sam Slutsky | 28%upside $101 | Outperform Maintained | 23 Jul 2025 |
Guggenheim Yatin Suneja | 28%upside $101 | Buy Maintained | 23 Jul 2025 |
JMP Securities Jason Butler | 20%upside $95 | Market Outperform Maintained | 23 Jul 2025 |
Financial journalist opinion
Positive
The Motley Fool
3 weeks ago
This Stock Is Up by 800% This Year -- but Is It a Buy?
If you had invested money in Abivax (ABVX 0.73%) at the beginning of the year, you would be sitting pretty right now. The French biotech's shares recently skyrocketed and are up more than 800% year to date.
Neutral
GlobeNewsWire
4 weeks ago
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters' option to purchase additional ADSs (the “Underwriters' Option”).
Neutral
GlobeNewsWire
1 month ago
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Positive
Seeking Alpha
1 month ago
Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst
Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, achieving significant clinical remission at 8 weeks induction period. Both ABTECT-1 and ABTECT-2 studies showed statistically significant results, supporting obefazimod's differentiated safety and efficacy profile as a first-in-class oral miR-124 enhancer. The next major catalyst is the 44-week maintenance trial data, expected in Q2 2026, which could enable a New Drug Application filing of obefazimod in H2 2026.
Neutral
GlobeNewsWire
1 month ago
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m.
Neutral
GlobeNewsWire
1 month ago
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States at an offering price of $64.00 per ADS (the “Offering”).
Neutral
GlobeNewsWire
1 month ago
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m.
Neutral
GlobeNewsWire
1 month ago
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company in the United States (the “Offering”).
Positive
Seeking Alpha
1 month ago
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity
Obefazimod's strong Phase 3 induction data positions Abivax as a leading UC contender, with a novel mechanism and favorable safety profile. The ABTECT program's robust design and inclusion of hard-to-treat patients de-risk obefazimod's path to approval, though maintenance data in 2026 remains pivotal. Obefazimod's differentiation lies in efficacy without serious safety risks, targeting a multi-billion dollar market despite intense competition from established and emerging drugs.
Positive
Investors Business Daily
1 month ago
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug.
Charts implemented using Lightweight Charts™